Inhibrx Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	216.52	152.6	277.92	-
Cash & Short-Term Investments	216.52	152.6	277.92	-
Cash Growth	-	-45.09%	-	-
Accounts Receivable	0.21	0.4	0.78	0.24
Other Receivables	-	0.02	-	0.01
Receivables	0.21	0.42	0.78	0.26
Inventory	1.89	2	9.89	0.81
Prepaid Expenses	2.67	4.19	5.67	4.53
Other Current Assets	2.09	1.2	1.09	0.67
Total Current Assets	223.39	160.4	295.36	6.26
Property, Plant & Equipment	12.45	13.54	9.37	7.22
Other Long-Term Assets	6.8	6.83	3.16	3.16
Total Assets	242.64	180.77	307.89	16.65
Accounts Payable	17.58	14.89	33.76	9.45
Accrued Expenses	24.09	24.25	20.49	9.46
Current Portion of Leases	1.97	1.6	2.06	1.86
Total Current Liabilities	43.64	40.73	56.31	20.77
Long-Term Debt	98.65	-	206.97	-
Long-Term Leases	5.9	6.45	1.11	3.17
Total Liabilities	148.2	47.18	264.39	23.95
Common Stock	0	0	0.01	-7.3
Additional Paid-In Capital	243.89	239.72	657.23	-
Retained Earnings	-149.44	-106.13	-613.73	-
Shareholders' Equity	94.44	133.58	43.5	-7.3
Total Liabilities & Equity	242.64	180.77	307.89	16.65
Total Debt	106.53	8.05	210.14	5.03
Net Cash (Debt)	109.99	144.55	67.78	-5.03
Net Cash Growth	-	113.25%	-	-
Net Cash Per Share	7.12	9.65	5.75	-
Filing Date Shares Outstanding	14.48	14.48	11.78	-
Total Common Shares Outstanding	14.48	14.48	11.78	-
Working Capital	179.75	119.67	239.05	-14.51
Book Value Per Share	6.52	9.23	3.69	-
Tangible Book Value	94.44	133.58	43.5	-7.3
Tangible Book Value Per Share	6.52	9.23	3.69	-
Machinery	10.31	10.31	9.02	7.55
Construction In Progress	0.02	-	3.59	-
Leasehold Improvements	0.8	0.8	0.44	0.44

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q